BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Velsipity (etrasimod) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Velsipity (etrasimod)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07782242-13@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Velsipity (etrasimod): Phase 4 readout est. (NCT07782242)
DESCRIPTION:Velsipity (etrasimod)\, phase 4\, Ulcerative Colitis.\nStudy: C
 omaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chines
 e Adults With Active UC\nEstimated primary completion: 30 June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/etrasimod#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07782242
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243639-13@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Velsipity (etrasimod): Phase na readout est. (NCT07243639)
DESCRIPTION:Velsipity (etrasimod)\, phase na\, Ulcerative Colitis.\nStudy: 
 Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colit
 is\nEstimated primary completion: 30 September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07243639
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287126-13@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290616
DTEND;VALUE=DATE:20290617
SUMMARY:Velsipity (etrasimod): Phase 2 readout est. (NCT05287126)
DESCRIPTION:Velsipity (etrasimod)\, phase 2\, Ulcerative Colitis.\nStudy: A
  Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Coli
 tis\nEstimated primary completion: 16 June 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05287126
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03950232-13@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290619
DTEND;VALUE=DATE:20290620
SUMMARY:Velsipity (etrasimod): Phase 3 readout est. (NCT03950232)
DESCRIPTION:Velsipity (etrasimod)\, phase 3\, Ulcerative Colitis.\nStudy: A
 n Extension Study for Treatment of Moderately to Severely Active Ulcerativ
 e Colitis\nEstimated primary completion: 19 June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03950232
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486921-13@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20300206
DTEND;VALUE=DATE:20300207
SUMMARY:Velsipity (etrasimod): Phase 2 readout est. (NCT07486921)
DESCRIPTION:Velsipity (etrasimod)\, phase 2.\nStudy: Etrasimod as Preventio
 n of Pouchitis\nEstimated primary completion: 6 February 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07486921
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07470879-13@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20300908
DTEND;VALUE=DATE:20300909
SUMMARY:Velsipity (etrasimod): Phase 2 readout est. (NCT07470879)
DESCRIPTION:Velsipity (etrasimod)\, phase 2\, Ulcerative Colitis.\nStudy: A
  Study of How the Medicine Called "Etrasimod" Works in Children With the G
 ut Disease Called Ulcerative Colitis\nEstimated primary completion: 8 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etrasimod
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 70879
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
